Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

0.4889 -0.0011 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For July 29, 2022
Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million. 
Via Benzinga
‘Baby with the Bathwater’ Biotechs (IPA, NRXP, PRFX, LEXX, LQDI)
Via AB Newswire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
From ImmunoPrecise Antibodies
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding (NYSE:BABA) is the largest... 
Via Benzinga
ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. 
Via Benzinga
Immunity Focused Biotherapeutic Developer with a Hybrid of Services and Technology for a Wide Range of Applications: ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)
Via Get News
Topics Artificial Intelligence
Exposures Artificial Intelligence
Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
Via AB Newswire
Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
Via AB Newswire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
From ImmunoPrecise Antibodies
Via Business Wire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
From ImmunoPrecise Antibodies
Via Business Wire
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
From ImmunoPrecise Antibodies
Via Business Wire
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
From ImmunoPrecise Antibodies
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena... 
Via Benzinga
Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail
Elektrofi and Immunoprecise Antibodies Ltd (NASDAQ: IPA) have collaborated to explore a high-concentration formulation of IPA's COVID-19 antibody... 
Via Benzinga
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
From Elektrofi and ImmunoPrecise Antibodies
Via Business Wire
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Immunoprecise's COVID-19 Antibody Cocktail Shows Favorable Safety, Toxicity Profile
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has reported preclinical data of PolyTope TATX-03 antibody cocktail therapy against COVID-19. The IND-enabling animal studies did... 
Via Benzinga
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-... 
Via Benzinga
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.